Eli Lilly and Company notes that the approval of an every-8-week maintenance dose of lebrikizumab offers sustained atopic dermatitis control with fewer annual injections.
Feliza Mirasol
Advertisement
Feliza Mirasol is the science editor for BioPharm International.
Articles by Feliza Mirasol
FDA's CBER details a framework for sponsors to apply existing CMC, nonclinical, and clinical data to genome-editing-based product development and regulatory filings.
Bristol Myers Squibb and Hengrui Pharma launch a multibillion-dollar collaboration spanning 13 oncology, hematology, and immunology programs to expand global drug development pipelines and accelerate early-stage clinical innovation.
Approval of Biogen's high-dose Spinraza strengthens the company’s lifecycle strategy in SMA, enhancing durability while reinforcing competitive positioning in a rapidly evolving neurology market.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharma Funding Roudup: Kardigan Announces $400 Million Initial IPO, cAMPfield Launches with $180 million Series A
2
FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010
3
Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010
4
Additive Manufacturing's Application in Pharma and Biotech
5